STAT3 and cholangiocarcinoma: Similarly, myricetin treatment potently inhibited the cytokine-induced migration and invasion of KKU-100 cholangiocarcinoma cells, mediated partially through STAT3 suppression; myricetin also suppressed downstream target genes of STAT3, including ICAM-1, MMP-9, iNOS, and COX-2 [148].